Foghorn Therapeutics (FHTX) Competitors $4.83 -0.27 (-5.29%) Closing price 04:00 PM EasternExtended Trading$4.74 -0.09 (-1.76%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FHTX vs. VERV, LENZ, PRAX, RCUS, AVXL, GPCR, SYRE, AKBA, PHAR, and CRONShould you be buying Foghorn Therapeutics stock or one of its competitors? The main competitors of Foghorn Therapeutics include Verve Therapeutics (VERV), LENZ Therapeutics (LENZ), Praxis Precision Medicines (PRAX), Arcus Biosciences (RCUS), Anavex Life Sciences (AVXL), Structure Therapeutics (GPCR), Spyre Therapeutics (SYRE), Akebia Therapeutics (AKBA), Pharming Group (PHAR), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry. Foghorn Therapeutics vs. Its Competitors Verve Therapeutics LENZ Therapeutics Praxis Precision Medicines Arcus Biosciences Anavex Life Sciences Structure Therapeutics Spyre Therapeutics Akebia Therapeutics Pharming Group Cronos Group Verve Therapeutics (NASDAQ:VERV) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation. Do insiders & institutionals have more ownership in VERV or FHTX? 97.1% of Verve Therapeutics shares are owned by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are owned by institutional investors. 19.3% of Verve Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is VERV or FHTX more profitable? Verve Therapeutics has a net margin of -303.64% compared to Foghorn Therapeutics' net margin of -311.90%. Foghorn Therapeutics' return on equity of 0.00% beat Verve Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Verve Therapeutics-303.64% -35.81% -27.57% Foghorn Therapeutics -311.90%N/A -28.00% Do analysts prefer VERV or FHTX? Verve Therapeutics currently has a consensus price target of $14.57, indicating a potential upside of 30.92%. Foghorn Therapeutics has a consensus price target of $10.67, indicating a potential upside of 120.84%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Foghorn Therapeutics is more favorable than Verve Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verve Therapeutics 0 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33Foghorn Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.17 Which has more risk and volatility, VERV or FHTX? Verve Therapeutics has a beta of 2.23, suggesting that its share price is 123% more volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.05, suggesting that its share price is 205% more volatile than the S&P 500. Which has higher valuation & earnings, VERV or FHTX? Foghorn Therapeutics has lower revenue, but higher earnings than Verve Therapeutics. Verve Therapeutics is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerve Therapeutics$32.33M30.69-$198.71M-$2.11-5.27Foghorn Therapeutics$22.60M12.08-$86.62M-$1.19-4.06 Does the media favor VERV or FHTX? In the previous week, Verve Therapeutics had 1 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 1 mentions for Verve Therapeutics and 0 mentions for Foghorn Therapeutics. Verve Therapeutics' average media sentiment score of 0.00 equaled Foghorn Therapeutics'average media sentiment score. Company Overall Sentiment Verve Therapeutics Neutral Foghorn Therapeutics Neutral SummaryVerve Therapeutics and Foghorn Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FHTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FHTX vs. The Competition Export to ExcelMetricFoghorn TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$288.30M$3.06B$5.75B$9.64BDividend YieldN/A2.22%3.91%4.09%P/E RatioN/A20.6130.7825.12Price / Sales12.08360.20458.48157.26Price / CashN/A41.5625.2228.45Price / Book-3.559.509.365.94Net Income-$86.62M-$54.72M$3.26B$265.56M7 Day Performance-0.82%2.39%1.83%0.95%1 Month Performance-21.21%4.60%3.69%2.47%1 Year Performance-36.20%9.11%28.88%20.24% Foghorn Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FHTXFoghorn Therapeutics2.2825 of 5 stars$4.83-5.3%$10.67+120.8%-18.5%$288.30M$22.60M0.00120VERVVerve Therapeutics3.0718 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110LENZLENZ Therapeutics2.0199 of 5 stars$38.77+11.8%$49.60+27.9%+70.4%$989.15MN/A-20.41110Gap UpHigh Trading VolumePRAXPraxis Precision Medicines1.8244 of 5 stars$44.95-2.2%$95.22+111.8%-11.8%$966.84M$8.55M-3.66110RCUSArcus Biosciences2.0292 of 5 stars$9.19+1.4%$21.14+130.2%-33.0%$964.27M$258M-2.90500AVXLAnavex Life Sciences3.7216 of 5 stars$11.35+2.4%$44.00+287.7%+57.5%$946.42MN/A-20.6440Earnings ReportGPCRStructure Therapeutics2.2925 of 5 stars$17.51+7.4%$75.71+332.4%-46.2%$939.42MN/A-16.68136Gap UpSYRESpyre Therapeutics2.8388 of 5 stars$15.25+0.6%$53.40+250.2%-34.9%$915.68M$890K-4.4973Positive NewsAKBAAkebia Therapeutics3.9026 of 5 stars$3.35-2.0%$6.75+101.5%+116.0%$906.80M$160.18M-19.70430PHARPharming Group2.1277 of 5 stars$12.10-8.5%$30.00+147.9%+59.7%$906.45M$297.20M-93.08280High Trading VolumeCRONCronos Group1.0853 of 5 stars$2.67+16.1%N/A+3.3%$882.76M$117.61M53.40450High Trading Volume Related Companies and Tools Related Companies Verve Therapeutics Competitors LENZ Therapeutics Competitors Praxis Precision Medicines Competitors Arcus Biosciences Competitors Anavex Life Sciences Competitors Structure Therapeutics Competitors Spyre Therapeutics Competitors Akebia Therapeutics Competitors Pharming Group Competitors Cronos Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FHTX) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Foghorn Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access